Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00098553 · ClinicalTrials.gov registry record · Phase 2
Everolimus in Treating Patients With Stage IV Melanoma
A Phase 2 study, sponsored by Alliance for Clinical Trials in Oncology.
- Completed
- Registry status
- Phase 2
- Development phase
- 53
- Enrollment target
NCT00098553 is a Phase 2 study that has completed, run by Alliance for Clinical Trials in Oncology. The registered enrollment target is 53 participants.
The verdict
NCT00098553, a Phase 2 study, has completed, sponsored by Alliance for Clinical Trials in Oncology.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 53 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy, such as everolimus, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Everolimus may also stop the growth of melanoma by blocking blood flow to the tumor. PURPOSE: This phase II trial is studying how well everolimus works in treating patients with stage IV melanoma.
Interventions
- DRUG everolimus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 53 participants |
| Start Date | 2005-04 |
| Est. Completion | 2010-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00098553
The ClinicalTrials.gov registry entry for NCT00098553 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 53 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Alliance for Clinical Trials in Oncology, which has 446 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which everolimus is the first listed.
NCT00098553 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00098553 about?
NCT00098553 is a clinical study titled "Everolimus in Treating Patients With Stage IV Melanoma". RATIONALE: Drugs used in chemotherapy, such as everolimus, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Everolimus may also stop the growth of melanoma by blocking blood flow to the tumor. PURPOSE: This phase II trial is st...
What is the current status of trial NCT00098553?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 53 participants. The study started on 2005-04. Estimated completion is 2010-02.
What interventions are being tested in trial NCT00098553?
The interventions under investigation include: everolimus (DRUG).
Who is sponsoring clinical trial NCT00098553?
This trial is sponsored by Alliance for Clinical Trials in Oncology, which has 446 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.